4:55 PM
 | 
Nov 16, 2012
 |  BC Extra  |  Company News

BMS receives option for Biocon's oral insulin analog

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) granted Bristol-Myers Squibb Co. (NYSE:BMY) an exclusive option to license worldwide rights outside of India to diabetes product IN-105. Biocon will further characterize the oral insulin analog through Phase II testing, after which...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >